Nomad Power Solutions (NMAD) vs PDS Biotechnology (PDSB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PDS Biotechnology (PDSB) has outperformed Nomad Power Solutions (NMAD) over the past year, gaining 2.0% versus a loss of 11.2%. Over five years, NMAD leads with a -77.2% price change compared with -91.7% for PDSB. PDS Biotechnology is the larger company by market cap ($100.0 million vs $72.9 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NMAD | PDSB |
|---|---|---|
| Share price | $4.53 | $1.38 |
| Market cap | $72.94M | $100.01M |
| 1-day change | +6.09% | +35.29% |
| YTD return | +8.65% | +32.47% |
| 1-year return | -11.23% | +2.00% |
| 5-year return | -77.17% | -91.73% |
| EPS (TTM) | $-1.01 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.38 | $1.55 |
| 52-week low | $2.36 | $0.195 |
| Distance from 52-week high | -45.94% | -10.97% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +262.32% |
| Average volume | 273.42K | 23.24M |
| Shares outstanding | 16.10M | 72.47M |
| Employees | — | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PDSB has outperformed NMAD by 13.2 percentage points over the past year.
About Nomad Power Solutions
NMAD stock →NOMAD Power Solutions, Inc. develops utility-scale mobile energy storage systems on providing transportable solutions.
Health Care · Biotechnology: Pharmaceutical Preparations
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
NMAD vs PDSB FAQ
Which is bigger, Nomad Power Solutions or PDS Biotechnology?
PDS Biotechnology (PDSB) is larger, with a market capitalization of $100.01M compared with $72.94M for Nomad Power Solutions (NMAD).
Which stock has performed better over the past year, NMAD or PDSB?
PDSB returned +2.00% over the past 12 months, compared with -11.23% for NMAD (price return, excluding dividends). Past performance does not predict future results.
Are Nomad Power Solutions and PDS Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.